Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.

Wai H Lim,Steve J Chadban,Scott Campbell,Hannah Dent,Graeme R Russ,Stephen P McDonald

NEPHROLOGY（2010）

引用 17|浏览9

暂无评分

摘要

This registry analysis suggests that IL-2Ra induction may be associated with a reduction in rejection risk in cyclosporine-treated intermediate immunological risk recipients, but not in low-risk renal transplant recipients.

查看译文

关键词

ANZDATA registry,cyclosporine,IL-2 receptor antibody,intermediate-risk,kidney transplant,low-risk

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要